News
![Puma Biotechnology to Present at the Credit Suisse Healthcare Conference](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
![IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting
IMV Inc. (Nasdaq:IMV)(TSX:IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that translational data, including comprehensive immune
![Puma Biotechnology Reports Third Quarter 2019 Financial Results](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Puma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for
![Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report
![IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter
![Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic
![Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today
![Clovis Oncology Announces Third Quarter 2019 Operating Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
![Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will
![Sangamo Therapeutics Announces New Scientific Advisory Board](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sangamo Therapeutics Announces New Scientific Advisory Board
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry
![Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31
![Savara Reports Third Quarter 2019 Financial Results and Provides Business Update](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.
“Based on the totality
![Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
![Epigenomics: Management steht das Wasser bis zum Hals!](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Epigenomics: Management steht das Wasser bis zum Hals!
Nach dem Kursdesaster vom Montag – die Aktie stürzte unter 1 Euro – sind die Verantwortlichen bei Epigenomics (WKN: A11QW5) alarmiert und beruhigen den Markt mit einer extra lancierten Pressemeldung
![co.don: Einstiegschance durch Kapitalerhöhung?](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
co.don: Einstiegschance durch Kapitalerhöhung?
Zu den größeren Verlierern am deutschen Aktienmarkt gehört heute das Papier von co.don (WKN: A1K022). So verliert die Aktie knapp -9% an Wert, weil das Unternehmen gestern Abend eine größere
![Assembly Bioscience: Durchbruch in der Hepatits-Forschung?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Assembly Bioscience: Durchbruch in der Hepatits-Forschung?
Die Aktie des Biotechnologie-Unternehmens Assembly Bioscience (WKN: A117S1) konnte sich kürzlich innerhalb von nur zwei Tagen verdoppeln. Grund hierfür war, dass Anleger einen vermeintlichen
![Biofrontera: Beruhigungstropfen vom Vorstand](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Biofrontera: Beruhigungstropfen vom Vorstand
Es wirkt wie ein Beruhigungstropfen für nervöse Anleger in Biofrontera-Aktien (WKN: 604611): CEO Prof. Dr. Hermann Lübbert kaufte laut offizieller Stimmrechtsmitteilung von gestern am Freitag und
![4SC: Wichtig für Aktionäre!](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
4SC: Wichtig für Aktionäre!
4SC AG (WKN: A14KL7) hatte in den letzten Septembertagen wissenschaftliche Updates zu ihren beiden Medikamentenkandidaten in der klinischen Entwicklung – Resminostat und Domatinostat – bekannt
![Biofrontera: Insider-Käufe nach Ameluz-Schock!](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Biofrontera: Insider-Käufe nach Ameluz-Schock!
Haben Sie schon zu vermeintlichen Schnäppchenpreisen zugeschlagen und Biofrontera-Aktien (WKN: 604611) gekauft? Diese Frage kann Biofrontera-CEO Prof. Dr. Hermann Lübbert mit einem klaren ‚Ja‘
![Biofrontera: Anleger zeigen sich schwer enttäuscht!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Biofrontera: Anleger zeigen sich schwer enttäuscht!
Heute Vormittag meldete die Leverkusener Biofrontera (WKN: 604611) ihre vorläufigen, natürlich noch nicht geprüften und somit nicht testierten, Geschäftszahlen für die ersten neun Monate des
![Clinuvel nach Zulassung und +1.500% – das ist der Nachfolger!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clinuvel nach Zulassung und +1.500% – das ist der Nachfolger!
Clinuvel-Aktionäre (WKN: A0JEGY) feiern die US-Zulassung des Medikaments Scenesse gegen eine seltene Hauterkrankung, die zu extremer Lichtempflichkeit führt. Die Aktie kann nun eine Kursrallye von
![DGAP-News: Expedeon AG: Expedeon AG gibt Umstellung auf Namensaktien bekannt](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
DGAP-News: Expedeon AG: Expedeon AG gibt Umstellung auf Namensaktien bekannt
![DGAP-News: Expedeon AG: Expedeon AG announces conversion to registered shares](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
DGAP-News: Expedeon AG: Expedeon AG announces conversion to registered shares
![DGAP-News: Epigenomics AG: Ergebnisse des Mikrosimulationsmodells werden auf renommierter Health Conference präsentiert](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)